
table of contents
The news overlapped in both areas: pharmaceutical regulations and industry.
It has been reported that the U.S. FDA has issued a request for information regarding clinical trials of "ibogaine" and has presented a draft of an early-stage trial design.
at the same time,サイケThe public comment period for Delix's final guidance has ended.
In terms of business, comments regarding Compass Pathways' pricing; in terms of intellectual property and market, LSD The brand name candidates for psilocybin have been discussed.
All of these topics relate to future access to treatment and market development.
概況
The FDA,サイケWe notified you of a Request for Information (RFI) related to the clinical research of ibogaine at the same time we closed the call for comments on the final guidance regarding the "future therapeutic use" of Derix.
The notification provides a draft design for early-stage clinical trials and is said to be in line with the principles of the guidance.
On the private side, there were talks about the pricing of Compass Pathways,LSDThis section summarizes discussions about potential brand names for psilocybin.
Source
| Classification | Key points | Source |
|---|---|---|
| Regulation/Policy | The FDA has issued a Request for Inquiry (RFI) for the ibogaine clinical trial, presenting a proposed initial trial design. The comment period for the final guidance on psychedelics has ended. | Psychedelic Alpha |
| Business | A talk about pricing for Compass Pathways was presented. | Psychedelic Alpha |
| Market and Intellectual Property | The potential brand names for LSD and psilocybin are generating buzz. | Psychedelic Alpha |
By topic
Research/Clinical
The FDA has issued a Request for Inquiry (RFI) for the ibogaine clinical trial, which reportedly outlines a proposed design for an early-stage clinical trial.
This is explained as being in line with the guidelines of the final guidance on clinical research of psychedelics.
By outlining the "design philosophy" for initial testing, researchers and development companies can more easily share directions for safety management and evaluation criteria.
However, specific protocols and numerical values have not been provided.
(reference)
Ibogaine is a compound found in plants native to Africa.サイケデリックIt has been shown to have effects and has been the subject of research on addiction and other related issues. RFI stands for "Request for Information," and it is a procedure in which regulatory authorities gather information for consideration.
Regulation/Policy
The FDA's public comment period for its "Considerations for Psychedelics for Future Therapeutic Use" has ended.
The timing of the RFI for ibogaine suggests that regulatory issues and considerations for its implementation in clinical practice will proceed in parallel.
Although no changes to the system have been announced, this information will serve as fundamental data that will impact future review and test design practices.
(reference)
Business and Corporate Trends
It has been reported that Compass Pathways gave a talk about pricing.
The specific price and timing have not been indicated.
The topic of pricing directly impacts insurance reimbursement and the hurdles to adoption by medical institutions.
Corporate statements influence investor and healthcare professionals' expectations, so further detailed disclosures will be closely watched.
(reference)
Market, intellectual property, and branding
The brand names for LSD and psilocybin are being discussed as potential candidates.
Brand names are related to trademarks and how doctors and patients perceive them, and they also affect awareness and the management of confusion risks after a product is launched.
Specific candidate names and registration status are not provided.
(reference)
A "brand name (product name)" is a name given separately from the generic name (active ingredient name). In the case of pharmaceuticals, ease of memorization and safety (prevention of mix-ups) are also considered.
This week's highlights
- FDA Ibogaine RFIThis provides guidance on initial trial designs, facilitating preparations at research sites (details are not publicly available). (Same source)
- The comment period for the guidance has ended.Discussions on the practical aspects of clinical and regulatory review for psychedelics are moving to the next stage. (Same source)
- Price and brand topicsCompass's pricing talk indicates that potential brand names for LSD/psilocybin will influence treatment access and market development prospects (specific details not yet released). (Same source)

![Mail-order product: MDMA × MM Analog [For Research Use]](https://www.thch-vape.shop/html/user_data/assets/img/products/213_250x250.webp)


